{"product_id":"tl1a-antibody-tnfsf15-vegi-bha17113818","title":"TL1A Antibody \/ TNFSF15 \/ VEGI","description":"\u003ch2\u003eOverview\u003c\/h2\u003e \u003cp\u003eTL1A Antibody \/ TNFSF15 \/ VEGI is a research-use primary antibody intended for detection of \u003cstrong\u003eTL1A\u003c\/strong\u003e in experimental workflows. It is supplied in \u003cstrong\u003ePurified\u003c\/strong\u003e format. Key antibody attributes include Mouse, Monoclonal (mouse origin), clone VEGI\/1283, isotype Mouse IgG1, kappa. Applications listed for this product include IHC-P. Reported\/annotated localization context: Cytoplasmic, cell surface, secreted. Species reactivity (as provided): Human.\u003c\/p\u003e \u003ch2\u003eKey elements and design rationale\u003c\/h2\u003e \u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eTarget:\u003c\/strong\u003e TL1A — selectivity and interpretation should be considered in the context of isoforms, post-translational modifications, and related family members when applicable.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormat:\u003c\/strong\u003e Purified — format can influence background, multiplexing compatibility, and downstream detection strategies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAntibody identity:\u003c\/strong\u003e Mouse, Monoclonal (mouse origin), clone VEGI\/1283, isotype Mouse IgG1, kappa — these attributes help align secondary reagents and controls (e.g., isotype-matched controls) with your assay design.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eLocalization:\u003c\/strong\u003e Cytoplasmic, cell surface, secreted — expected subcellular distribution can guide band\/structure interpretation and help flag off-target signal.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eProduct notes (from provided description):\u003c\/strong\u003e TNF ligand-related molecule 1 is an anti-angiogenic cytokine that is also called Tumor necrosis factor superfamily, member 15 (TNFSF15) and Vascular endothelial growth inhibitor (VEGI\/VEGI192A). This protein is abundantly expressed in endothelial cells, but is not expressed in either B or T cells. The expression of this protein is inducible by TNF and IL-1 alpha. This cytokine is a ligand for receptor TNFRSF25 and decoy receptor TNFRSF21\/DR6. It can activate NF-kappaB and MAP kinases, and acts as an autocrine factor to induce apoptosis in endothelial cells. This cytokine is also found to inhibit endothelial cell proliferation, and thus may function as an angiogenesis inhibitor. Reduced expression of TL1A has been reported as a marker of poor prognosis in breast cancer.\u003c\/li\u003e\n\u003c\/ul\u003e \u003cp\u003eWhere multiple assay formats are possible, align the antibody format, host\/isotype, and listed applications with your detection system and controls to support clear interpretation of signal.\u003c\/p\u003e \u003ch2\u003eBiological background\u003c\/h2\u003e \u003cp\u003eIn this catalog, TL1A is positioned within \u003cstrong\u003eImmunology \u0026amp; Inflammation, Cancer, Tumor\u003c\/strong\u003e research contexts. Localization annotations (e.g., Cytoplasmic, cell surface, secreted) can help contextualize expected signal patterns in imaging and fractionation-based readouts. For authoritative gene\/protein nomenclature, domains\/isoforms, and curated functional annotations, consult resources such as UniProt, NCBI Gene, and Ensembl.\u003c\/p\u003e \u003ch2\u003eResearch relevance and current trends\u003c\/h2\u003e \u003cul\u003e\n\u003cli\u003eHigher-plex and spatially resolved readouts (e.g., multiplex IF\/IHC, spatial omics) are increasing demand for well-characterized primary antibodies with clearly stated host\/isotype and labeling strategies.\u003c\/li\u003e\n\u003cli\u003eGenetic perturbation controls (knockout\/knockdown) and orthogonal measurements (e.g., RNA vs protein) are commonly used to strengthen target attribution when interpreting antibody-derived signals.\u003c\/li\u003e\n\u003cli\u003eReproducibility initiatives emphasize transparent reporting of antibody identity (clone, host, isotype) and experimental context to improve cross-study comparability.\u003c\/li\u003e\n\u003c\/ul\u003e \u003ch2\u003eCommon research applications\u003c\/h2\u003e \u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eIHC-P:\u003c\/strong\u003e interpret changes in signal in the context of sample composition, epitope accessibility, and potential isoform\/PTM differences across conditions.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTypical workflow themes:\u003c\/strong\u003e IHC on FFPE tissue, ELISA binding assay, Specificity controls.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eWorkflow notes:\u003c\/strong\u003e Detect TNFSF15 by IHC in FFPE tissue sections (optimize antigen retrieval + dilution), Measure binding to TNFSF15 peptide\/protein by ELISA with dilution series (include blanks), Confirm specificity using KO\/KD or pept…\u003c\/li\u003e\n\u003c\/ul\u003e \u003cp\u003eWhen comparing conditions, consistent sample processing and appropriate negative\/positive controls support interpretation of qualitative localization differences and quantitative abundance changes.\u003c\/p\u003e \u003ch2\u003eNotes for experimental interpretation\u003c\/h2\u003e \u003cul\u003e\n\u003cli\u003eIsoforms and post-translational modifications may shift apparent molecular weight or epitope accessibility, especially across cell states or treatments.\u003c\/li\u003e\n\u003cli\u003eSpecies and tissue context can affect sequence conservation, expression level, and background binding; predicted reactivity should be verified in your sample.\u003c\/li\u003e\n\u003cli\u003eControl concepts include isotype-matched controls, secondary-only controls (for indirect detection), and genetic\/orthogonal controls (e.g., KO\/KD, independent antibodies, or RNA measurements) when feasible.\u003c\/li\u003e\n\u003c\/ul\u003e \u003cp\u003eMonoclonal and polyclonal antibodies can differ in epitope recognition breadth and lot-to-lot characteristics; consider clonality and clone information (when provided) alongside your assay requirements. Conjugated formats may simplify detection but can change background and multiplexing behavior compared with unconjugated primaries.\u003c\/p\u003e \u003c!-- Sources (internal): - UniProt Knowledgebase (UniProtKB) — UniProt Consortium — https:\/\/www.uniprot.org\/ - NCBI Gene — National Center for Biotechnology Information (NCBI) — https:\/\/www.ncbi.nlm.nih.gov\/gene\/ - Ensembl Genome Browser — EMBL-EBI — https:\/\/www.ensembl.org\/ - The Human Protein Atlas — Human Protein Atlas — https:\/\/www.proteinatlas.org\/ - Antibody validation concepts and controls (general guidance) — NIH \/ community resources — https:\/\/www.nih.gov\/ - MIQE\/experimental reporting \u0026 reproducibility (general) — Scientific community guidelines — https:\/\/www.equator-network.org\/ --\u003e","brand":"NSJ Bioreagents","offers":[{"title":"0.2 mg\/ml in 1X PBS with 0.1 mg\/ml BSA (US sourced) and 0.05% sodium azide \/ 100 ug","offer_id":53044916846957,"sku":"V3348-100UG","price":559.0,"currency_code":"USD","in_stock":true},{"title":"0.2 mg\/ml in 1X PBS with 0.1 mg\/ml BSA (US sourced) and 0.05% sodium azide \/ 20 ug","offer_id":53045033369965,"sku":"V3348-20UG","price":259.0,"currency_code":"USD","in_stock":true},{"title":"1 mg\/ml in 1X PBS; BSA free, sodium azide free \/ 100 ug","offer_id":53045033402733,"sku":"V3348SAF-100UG","price":559.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/get_image_183bf968-be19-4d49-9a24-6ce87d0b00c1.jpg?v=1782236847","url":"https:\/\/www.ebiohippo.com\/products\/tl1a-antibody-tnfsf15-vegi-bha17113818","provider":"BioHippo","version":"1.0","type":"link"}